[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100340458":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":46,"responsibleParty":71,"collaborators":10,"id":74,"slug":10,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":10,"enrollmentInfo":82,"targetDuration":10,"studyType":85,"phases":10,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Ludwig-Maximilians - University of Munich","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"neoadjuvant chemoradiation",null,"Patient with esophageal Cancer treated by neoadjuvant chemoradiation followed by surgery will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25",[13,14,15],"Other: EORTC QLQ C30","Other: EORTC QLQ OES-18","Other: EORTC OG-25",{"label":17,"type":10,"description":18,"interventionNames":19},"definitive chemoradiation","Patient with esophageal Cancer treated by definitive chemoradiation will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25",[13,14,15],[21,25,28],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"EORTC QLQ C30","standardized questionaire",[17,9],{"type":6,"name":26,"description":23,"armGroupLabels":27,"otherNames":10},"EORTC QLQ OES-18",[17,9],{"type":6,"name":29,"description":23,"armGroupLabels":30,"otherNames":10},"EORTC OG-25",[17,9],[32],{"name":33,"affiliation":34,"role":35},"Falk Roeder, MD","Ludwig-Maximilians Universität München","PRINCIPAL_INVESTIGATOR",[37,42],{"name":33,"role":38,"phone":39,"phoneExt":40,"email":41},"CONTACT","+49 89 4400","73729","Falk.Roeder@t-online.de",{"name":43,"role":38,"phone":39,"phoneExt":44,"email":45},"Franziska Walter, MD","73770","Franziska.Walter@med.uni-muenchen.de",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Department of Radiation Oncology, University Hospital, LMU Munich","RECRUITING","Munich","Bavaria","81377","Germany",{"type":55,"coordinates":56},"Point",[57,58],11.57549,48.13743,{"lat":58,"lon":57},[61,64,66,69],{"name":33,"role":38,"phone":62,"phoneExt":10,"email":63},"+49 89 4400 73729","Falk.Roeder@med.uni-muenchen.de",{"name":43,"role":38,"phone":65,"phoneExt":10,"email":45},"+49 89 4400 73770",{"name":67,"role":68,"phone":10,"phoneExt":10,"email":10},"Sabine Gerum, MD","SUB_INVESTIGATOR",{"name":70,"role":68,"phone":10,"phoneExt":10,"email":10},"Michael Hoffmann, MD",{"type":35,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Falk Roeder","Consultant","100340458",false,"NCT03712774","Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant or Definitive Chemoradiation in Patients With Esophageal Cancer","ESOCARE","Inclusion Criteria:\n\n* histologically proven esophageal Cancer (SCC or adenocarcinoma) without distant metastases (except supraclavicular nodes)\n* indication for neoadjuvant or definitive chemoradiation using either cisplatin\u002F5-FU or carboplatin\u002Fpaclitaxel with curative intent\n* age \\>= 18 years\n* written informed consent\n* ability to answer the standardized questionaires according to the treating physician\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* Treatment with palliative intent\n* distant metastases (except supraclavicular nodes)\n* second malignancy\n* Prior systemic treatment for esophageal Cancer\n* Treatment in an interventional study","ALL","18 Years",{"count":83,"type":84},60,"ESTIMATED","OBSERVATIONAL","Prospective observational study to evaluate the Quality of life based on standardized EORTC questionaires as well as toxicities, functional and oncological outcomes in patients treated with neoadjuvant or definitive chemoradiation for esophageal Cancer.",[88,89,90],"Quality of Life","Chemoradiation","Esophageal Cancer",[92,93,94,95,96],"quality of life","neoadjuvant","definitive","chemoradiation","esophageal cancer","2018-10-18",{"date":99,"type":100},"2018-10-19","ACTUAL",{"date":102,"type":100},"2018-10-12",{"date":104,"type":84},"2026-12-31",{"name":5,"class":6},1]